Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Empasiprubart by Argenx for Dermatomyositis: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Empasiprubart by Argenx for Multifocal Motor Neuropathy: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Multifocal Motor Neuropathy. According to GlobalData, Phase...
Empasiprubart by Argenx for Delayed Graft Function (DGF): Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Delayed Graft Function (DGF). According to GlobalData,...
Empasiprubart by Argenx for Dermatomyositis: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Risk adjusted net present value: What is the current valuation of Argenx's Empasiprubart?
Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy. According to...